Mixed results for Cerevance’s solengepras

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, untreated Parkinson’s disease, that failed to meet the primary endpoint of the study.

In the ASCEND trial, solengepras showed a small, non-statistically significant improvement in Parkinson’s disease motor symptoms from baseline to week 12 compared to placebo as assessed by the combined Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II+III. Those results were not statistically significant primarily because of the lack of differentiation between solengepras and placebo in the Part III physician-administered neurological exam, which assesses the physical signs of Parkinson’s disease at a single point in time.

The data were presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, in Vienna.